Literature DB >> 29602818

Perspective on How the FDA Should Review Diagnostic Radiopharmaceuticals.

Sally W Schwarz1, Bonnie Clarke2.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29602818     DOI: 10.2967/jnumed.117.204446

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  2 in total

Review 1.  Regulatory Agencies and PET/CT Imaging in the Clinic.

Authors:  Peter Herscovitch
Journal:  Curr Cardiol Rep       Date:  2022-08-01       Impact factor: 3.955

Review 2.  Imaging of T-cells and their responses during anti-cancer immunotherapy.

Authors:  Massis Krekorian; Gilbert O Fruhwirth; Mangala Srinivas; Carl G Figdor; Sandra Heskamp; Timothy H Witney; Erik H J G Aarntzen
Journal:  Theranostics       Date:  2019-10-16       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.